HbA1c
improvement in pregnant women with type 1 diabetes using the
CamAPS FX
automated insulin delivery (
AID
) syste
Maria‐Eleni Syleouni, Tara T. M. Lee, Federica Carrieri, Eleanor M. Scott, Aesha Khan Mirón, Helen R. Murphy Abstract
Aims
The Automated Insulin Delivery among Pregnant women with Type 1 diabetes (AiDAPT) trial demonstrated that using the CamAPS FX automated insulin delivery (AID) was associated with improved glycaemic outcomes. This study aimed to assess the clinical and economic impact of improving third‐trimester HbA1c.
Methods
Using the AiDAPT data, a health economics model was built to estimate clinical outcomes and healthcare resource utilisation associated with third‐trimester HbA1c categories (<42 mmol/mol, 42–53 mmol/mol, ≥53 mmol/mol). AiDAPT HbA1c distribution and associated clinical outcomes (obstetric: pre‐eclampsia, delivery method; neonatal: length of stay in normal/critical/intensive care) were used to estimate perinatal complications. UK‐specific healthcare costs were extracted from the NHS National Schedule and other published sources. Total costs to the UK healthcare system were estimated using an incremental 3.3 mmol/mol (0.3%) HbA1c reduction observed with CamAPS FX AID over Standard Care in AIDAPT.
Results
In the model, HbA1c improvement with CamAPS FX AID was associated with projected reductions in pre‐eclampsia risk (−13%), high dependency neonatal care days (−16%), neonatal intensive care unit days (−12%) and clinic visits. The model projected cost reduction for the NHS healthcare system of £6,696,636 under conservative modelling assumptions, being cost saving at 96.8% of the simulations. The projected incremental cost difference per woman treated with CamAPS FX AID was ‐£1016, mainly derived from a modelled shift in the distribution of neonatal care, with reduced length of stay in high dependency neonatal intensive care.
Conclusion
CamAPS FX AID improves third‐trimester HbA1c with projected cost reductions for the UK healthcare system.